Literature DB >> 24012200

Finasteride use in the male infertility population: effects on semen and hormone parameters.

Mary K Samplaski1, Kirk Lo, Ethan Grober, Keith Jarvi.   

Abstract

OBJECTIVE: To determine the degree of improvement in semen parameters after finasteride discontinuation.
DESIGN: A prospective database of men presenting for a fertility evaluation was analyzed for semen and hormone parameters before and after discontinuation of finasteride.
SETTING: A male infertility specialty clinic. PATIENT(S): Men presenting for fertility evaluation from 2008-2012 on finasteride. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Semen and hormone parameters before and after discontinuation of finasteride. RESULT(S): At presentation, 27 (0.6%) of 4,400 men on finasteride. The mean duration of treatment with finasteride was 57.4 months, and mean dose was 1.04 mg/day. There was an average 11.6-fold increase in sperm counts after finasteride discontinuation. Of the men with severe oligospermia (<5 M/mL), 57% had counts increase to >15 M/mL after finasteride cessation. No man had a decrease in sperm count. There was no change in hormone parameters, sperm motility, or sperm morphology. CONCLUSION(S): Finasteride, even at low doses, may cause reduced sperm counts in some men. In this population, counts improved dramatically for the majority of men after finasteride discontinuation. The hormone parameters, sperm motility, and sperm morphology were unchanged after cessation. Finasteride should be discontinued in subfertile men with oligospermia, and used with caution in men who desire fertility.
Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5α-reductase; Azoospermia; fertility; finasteride; oligospermia; semen; spermatogenesis

Mesh:

Substances:

Year:  2013        PMID: 24012200     DOI: 10.1016/j.fertnstert.2013.07.2000

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  18 in total

1.  The workup and management of azoospermic males.

Authors:  Keith Jarvi; Kirk Lo; Ethan Grober; Victor Mak; Anthony Fischer; John Grantmyre; Armand Zini; Peter Chan; Genevieve Patry; Victor Chow; Trustin Domes
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

Review 2.  [Impact of lifestyle and environmental factors on male reproductive health].

Authors:  H-C Schuppe; F-M Köhn
Journal:  Hautarzt       Date:  2018-12       Impact factor: 0.751

3.  Clomiphene citrate rescue of spermatogenesis in men with infertility while remaining on finasteride: A case report.

Authors:  Christopher Wu; Ellen Forbes; Keith Allen Jarvi
Journal:  Can Urol Assoc J       Date:  2017-03-16       Impact factor: 1.862

Review 4.  Hormone-Based Treatments in Subfertile Males.

Authors:  Darshan P Patel; Jason C Chandrapal; James M Hotaling
Journal:  Curr Urol Rep       Date:  2016-08       Impact factor: 3.092

Review 5.  Adverse effects of common medications on male fertility.

Authors:  Mary K Samplaski; Ajay K Nangia
Journal:  Nat Rev Urol       Date:  2015-06-23       Impact factor: 14.432

6.  Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function.

Authors:  Francesco Pallotti; Giulia Senofonte; Marianna Pelloni; Francesco Cargnelutti; Tania Carlini; Antonio F Radicioni; Alfredo Rossi; Andrea Lenzi; Donatella Paoli; Francesco Lombardo
Journal:  Endocrine       Date:  2020-02-12       Impact factor: 3.633

Review 7.  Androgenetic Alopecia: An Update of Treatment Options.

Authors:  Yanna Kelly; Aline Blanco; Antonella Tosti
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

Review 8.  The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.

Authors:  Mohammed A Said; Akanksha Mehta
Journal:  Curr Urol Rep       Date:  2018-06-16       Impact factor: 3.092

9.  [Drug treatment of alopecia].

Authors:  H Wolff
Journal:  Internist (Berl)       Date:  2015-10       Impact factor: 0.743

Review 10.  Fertility Options for the Transgender and Gender Nonbinary Patient.

Authors:  Allison C Mayhew; Veronica Gomez-Lobo
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.